Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
---|---|---|---|---|---|---|
Vera Therapeutics IncVERA | $43.83 | Strong Buy | $56.00 | +27.77% | 19 hours ago | |
Analyst RankingTop 5% #215 out of 4527 analysts Average Return+15.72% Win Rate58%72 out of 125 Risk vs RewardPoor Good Analyst ColorGuggenheim's Vamil Divan raised their price target on Vera Therapeutics (NASDAQ: VERA) by 107.4% from $27 to $56 on 2024/03/27. The analyst maintained their Strong Buy rating on the stock. Divan explained that their price target move followed updated Guggenheim analysis and "talks with leading nephrologists." The IgAN (IgA nephropathy or Berger disease) treatment market has seen "significant progress in recent years," the analyst detailed, and the key takeaway from the conversations with nephrologists was ramped sales estimates for Vera Therapeutics' atacicept. FootnotesFrom here: Atacicept is a recombinant fusion protein that contains the soluble TACI receptor that binds to the cytokines BLyS and APRIL. These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, such as IgA Nephropathy (IgAN) and lupus nephritis (LN). Blocking these cytokines with atacicept has been shown in clinical trials to reduce disease-causing antibodies. Vera Therapeutics holds an exclusive worldwide license for the development and commercialization of atacicept in all indications from Merck KGaA. | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | a day ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have a premium account? Sign In |